Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

OBJECTIVES: Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis B virus (HBV) co-infection. We present feasibilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolle, Charlotte-Paige, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson, Ramgopal, Moti, Leone, Peter A., Matthews, Jessica E., Dalessandro, Marybeth, Underwood, Mark R., Angelis, Konstantinos, Wynne, Brian R., Merrill, Deanna, Nguyen, Christopher, van Wyk, Jean, Zolopa, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462441/
https://www.ncbi.nlm.nih.gov/pubmed/34115650
http://dx.doi.org/10.1097/QAD.0000000000002979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462441/
https://www.ncbi.nlm.nih.gov/pubmed/34115650
http://dx.doi.org/10.1097/QAD.0000000000002979

Ejemplares similares